Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-231 Trametinib
0.001
MEK
MAPK/nRTK
 0.7626 0.05415
MDA-MB-231 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.4427 0.15621
MDA-MB-231 Trametinib
0.01
MEK
MAPK/nRTK
 0.0846 0.34837
MDA-MB-231 Trametinib
0.031623
MEK
MAPK/nRTK
 -0.0896 0.45010
MDA-MB-231 Trametinib
0.1
MEK
MAPK/nRTK
 -0.1466 0.48773
MDA-MB-231 Trametinib
0.31623
MEK
MAPK/nRTK
 -0.1785 0.52259
MDA-MB-231 Trametinib
1.0
MEK
MAPK/nRTK
 -0.1588 0.49327
MDA-MB-231 Saracatinib
0.001
SRC
MAPK/nRTK
 0.9358 0.00919
MDA-MB-231 Saracatinib
0.0031623
SRC
MAPK/nRTK
 0.9211 0.00509
MDA-MB-231 Saracatinib
0.01
SRC
MAPK/nRTK
 0.8679 0.00453
MDA-MB-231 Saracatinib
0.031623
SRC
MAPK/nRTK
 0.8683 0.01199
MDA-MB-231 Saracatinib
0.1
SRC
MAPK/nRTK
 0.7816 0.01483
MDA-MB-231 Saracatinib
0.31623
SRC
MAPK/nRTK
 0.7480 0.01945
MDA-MB-231 Saracatinib
1.0
SRC
MAPK/nRTK
 0.5590 0.03622
MDA-MB-231 Saracatinib
3.1623
SRC
MAPK/nRTK
 0.4964 0.02536
MDA-MB-231 Saracatinib
10.0
SRC
MAPK/nRTK
 0.2801 0.10952
MDA-MB-231 ABT-737
0.001
Bcl2/XL
Misc
 0.9967 0.00528
MDA-MB-231 ABT-737
0.0031623
Bcl2/XL
Misc
 0.9916 0.00527
MDA-MB-231 ABT-737
0.01
Bcl2/XL
Misc
 0.9978 0.00970
MDA-MB-231 ABT-737
0.031623
Bcl2/XL
Misc
 1.0471 0.01315
MDA-MB-231 ABT-737
0.1
Bcl2/XL
Misc
 1.0077 0.01724
MDA-MB-231 ABT-737
0.31623
Bcl2/XL
Misc
 0.9171 0.03305
MDA-MB-231 ABT-737
1.0
Bcl2/XL
Misc
 0.8064 0.06169
MDA-MB-231 ABT-737
3.1623
Bcl2/XL
Misc
 0.5016 0.17355
MDA-MB-231 ABT-737
10.0
Bcl2/XL
Misc
 -0.1204 0.39679